CAI
NASDAQ
US
Caris Life Sciences, Inc. - Common Stock
$19.29
▲ +$0.16
(+0.84%)
Vol 1.5M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$7.6B
Margin
-46.4%
D/E
78.70
Beta
0.30
52W
$23–$43
Wall Street Consensus
14 analysts · Apr 20266
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
ERAS
Erasca Inc
$1.1B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
Earnings
Beat rate: 66.7%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.03 | $0.28 | +$0.25 |
| Sep 2025 | $-0.21 | $0.08 | +$0.29 |
| Jun 2025 | $-0.20 | $-7.97 | $-7.77 |
Quarterly Revenue & Earnings
| Quarter | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|
| Revenue | $120.9M | $181.4M | $216.8M | $292.9M |
| Net Income | -$102.6M | -$71.8M | $24.3M | $82.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | — | — | — | — | — |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -39.6% | — | -63.9% | -63.9% | -46.4% | -46.4% |
| Gross Margin | 62.7% | — | 49.1% | 49.1% | 53.5% | 53.5% |
| D/E Ratio | 82.51 | — | 82.51 | 82.51 | 78.70 | 78.70 |
| Current Ratio | 9.24 | 1.05 | 9.24 | 9.24 | 9.93 | 9.93 |
Key Ratios
P/S (TTM)
8.17
EPS (TTM)
$-1.56
52W High
$42.50
52W Low
$22.86
$22.86
52-Week Range
$42.50
Financial Health
Free Cash Flow
$39.7M
Net Debt
-$368.6M
Cash
$796.3M
Total Debt
$427.7M
As of Dec 31, 2025
How does CAI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CAI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
8.2
▼
36%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
—
▼
0%
below
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CAI profitability vs Biotechnology peers
ROE
—
▼
0%
below
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-46.4%
▲
84%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
53.5%
▼
32%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
—
▼
0%
below
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CAI financial health vs Biotechnology peers
D/E ratio
78.7
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
9.9
▲
124%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
69%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CAI fundamentals radar
CAI
Peer median
Industry
CAI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio